Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521.

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. Oncologist. 2019.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839-6851.

Kondo M, Dalai SC, Venkatasubrahmanyam S, Eisenberg N, Robinson BD, Westblade LF, et al. Diagnosis and Genotyping of Endocarditis in a Patient with Prosthetic Pulmonary Valve Replacement Using Next-Generation Sequencing of Plasma Microbial Cell-Free DNA. Open Forum Infect Dis. 2019;6(6):ofz242.

Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, et al. Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'. Nat Genet. 2019;51(10):1427-1428.

Vossoughi S, Gorlin J, Kessler DA, Hillyer CD, Van Buren NL, Jimenez A, et al. Ten years of TRALI mitigation: measuring our progress. Transfusion. 2019;59(8):2567-2574.

Cushing MM, DeSimone RA, Goel R, Hsu Y-, Parra P, Racine-Brzostek SE, et al. The impact of Daratumumab on transfusion service costs. Transfusion. 2019;59(4):1252-1258.

Bartlett NL, Wilson WH, Jung S-, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-1799.

Magro CM, Ruan J, Grossman M, Hedayat AA. Monoclonal plasma cell infiltrates in the setting of cutaneous follicular helper T cell lymphoproliferative disorders. Ann Diagn Pathol. 2019;40:94-104.